AEZS - Aeterna Zentaris starts preclinical development of macimorelin in amyotrophic lateral sclerosis

Aeterna Zentaris (AEZS) has commenced the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), the most common motor neuron disease.The preclinical development program is part of the recently executed Material Transfer Agreement with The University of Queensland. The University researchers, will conduct preclinical studies in disease-related in-vitro and in-vivo models of ALS to demonstrate the therapeutic potential of macimorelin on disease progression and ALS-specific pathology.Recently, The University researchers have filed funding applications to dedicated organizations in Australia to finance parts of the preclinical development program and to conduct a subsequent clinical trial to evaluate the safety, tolerability and efficacy of macimorelin as a potential new treatment option for ALS patients. In the event of positive results, the Company has the exclusive right to acquire a license from The University on the therapeutic use of macimorelin for

For further details see:

Aeterna Zentaris starts preclinical development of macimorelin in amyotrophic lateral sclerosis